Discovery and Rational Design of a Novel Bowman-Birk Related Protease Inhibitor

Anuran amphibian skin secretions are a rich source of peptides, many of which represent novel protease inhibitors and can potentially act as a source for protease inhibitor drug discovery. In this study, a novel bioactive Bowman-Birk type inhibitory hexadecapeptide of the Ranacyclin family from the defensive skin secretion of the Fukien gold-striped pond frog, Pelophlax plancyi fukienesis, was successfully isolated and identified, named PPF-BBI. The primary structure of the biosynthetic precursor was deduced from a cDNA sequence cloned from a skin-derived cDNA library, which contains a consensus motif representative of the Bowman-Birk type inhibitor. The peptide was chemically synthesized and displayed a potent inhibitory activity against trypsin (Ki of 0.17 mu M), as well as an inhibitory activity against tryptase (Ki of 30.73 mu M). A number of analogues of this peptide were produced by rational design. An analogue, which substituted the lysine (K) at the predicted P-1 position with phenylalanine (F), exhibited a potent chymotrypsin inhibitory activity (Ki of 0.851 mu M). Alternatively, a more potent protease inhibitory activity, as well as antimicrobial activity, was observed when P-16 was replaced by lysine, forming K-16-PPF-BBI. The addition of the cell-penetrating peptide Tat with a trypsin inhibitory loop resulted in a peptide with a selective inhibitory activity toward trypsin, as well as a strong antifungal activity. This peptide also inhibited the growth of two lung cancer cells, H460 and H157, demonstrating that the targeted modifications of this peptide could effectively and efficiently alter its bioactivity.